This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-08 and is reviewed periodically as new material appears.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== International expansion == The chain first began expanding internationally in 2014, opening its first restaurant in Kuwait. The namesake mascot, a dog, is not seen on signage and merchandise, as dogs are not popular in Kuwait for religious reasons. The restaurant chain expanded to Dubai in 2024. In 2025, it was reported the company is planning to open stores in Mexico in 2026 with an agreement with Mexico's Alsea.
Other stressors that can stimulate increased solanine biosynthesis include mechanical damage, improper storage conditions, improper food processing, and sprouting. The largest concentration of solanine in response to stress is on the surface in the peel, making it an even better defense mechanism against pests trying to consume it.
Here, Mr(X) is the relative molar mass, also called molecular weight or formula weight. For normal samples from Earth with typical isotope composition, the standard atomic weight or the conventional atomic weight can be used as an approximation of the relative atomic mass of the sample. Examples are:
Hong Kong is governed by a hybrid regime that is not fully representative of the population. Legislative Council members elected by functional constituencies composed of professional and special-interest groups are accountable to narrow corporate electorates rather than the general public. This electoral arrangement has ensured a pro-Beijing majority in the legislature since the handover. Similarly, the chief executive is selected by establishment politicians and corporate members of the Election Committee rather than directly elected. Despite universal suffrage being established as ultimate goals for the election of the chief executive and all members of the Legislative Council in Articles 45 and 68 of the basic law, the legislature is only partially directly elected, and the executive continues to be nominated by an unrepresentative body. The government has been repeatedly petitioned to introduce direct elections for these positions, but has not introduced these direct elections as of 2026. Ethnic minorities (except those of European ancestry) have marginal representation in government and often experience discrimination in housing, education, and employment. Employment vacancies and public service appointments frequently have language requirements that minority job seekers do not meet, and language education resources remain inadequate for Chinese learners. Foreign domestic helpers, mostly women from the Philippines and Indonesia, have little protection under regional law.
Sources: en.wikipedia.org
The proposed 2 World Trade Center breaks ground in Lower Manhattan in New York City, New York, U.S., 25 years after the original building was destroyed during the September 11 attacks. July 10 2026 United States Senate elections: Graham Platner officially withdraws from the Senate race in Maine, with the Maine Secretary of State’s Office confirming his withdrawal. The Trump administration loosens export controls on the UAE. July 11 Housing in the United States: The 21st Century ROAD to Housing Act, a piece of legislation passed in the U.S. Congress to expand affordable housing and reduce housing costs in the United States, becomes law after U.S. president Donald Trump allows the bill to take effect without his signature. Iran war: Iran's IRGC navy says that it has closed the Strait until further notice after firing a warning shot at a vessel trying to transit through an unapproved route. Republican U.S. senator Lindsey Graham of South Carolina dies at his home in Washington, D.C., aged 71, following a brief and sudden illness. His death creates a vacancy in the United States Senate, with Governor Henry McMaster to appoint a temporary successor ahead of a special Republican primary to replace Graham as the party's nominee in the November election. July 12 2026 Iran war: The US Central Command says that the Iranian attack significantly damaged a Cyprus-flagged container vessel and a crew member went missing. Britain's military says that the vessel was nine nautical miles east of Oman and the attack forced the crew to abandon the vessel.
{\displaystyle {\begin{array}{rcl}\\{\ce {^{3}_{1}H}}&{\ce {->[12.32\ {\ce {y}}]}}&{\ce {{^{3}_{2}He}+e^{-}}}\\{\ce {^{4}_{1}H}}&{\ce {->[139\ {\ce {ys}}]}}&{\ce {{^{3}_{1}H}+{^{1}_{0}n}}}\\{\ce {^{5}_{1}H}}&{\ce {->[86\ {\ce {ys}}]}}&{\ce {{^{3}_{1}H}+{2_{0}^{1}n}}}\\{}\end{array}}}
Despite Cleverdon's urgings, the script slipped from Thomas's priorities and in January 1951 he went to Iran to work on a film for the Anglo-Iranian Oil Company, an assignment which Callard has speculated was undertaken on behalf of British intelligence agencies. Thomas toured the country with the film crew, and his letters home vividly express his shock and anger with the poverty he saw around him. He also gave a reading at the British Council and talked with a number of Iranian intellectuals, including Ebrahim Golestan whose account of his meeting with Thomas has been translated and published. The film was never made, with Thomas returning to Wales in February, though his time in Iran allowed him to provide a few minutes of material for a BBC documentary Persian Oil. Thomas' journey through Iran has also been the subject of the 2024 documentary film Pouring Water on Troubled Oil. The film was written and directed by Nariman Massoumi, Department of Film and Television at the University of Bristol, with narration by Michael Sheen. Later that year, Thomas published two poems, which have been described as "unusually blunt." They were an ode, in the form of a villanelle, to his dying father, Do not go gentle into that good night, and the ribald Lament. Although he had a range of wealthy patrons, including Margaret Taylor, Princess Marguerite Caetani and Marged Howard-Stepney, Thomas was still in financial difficulty, and he wrote several begging letters to notable literary figures, including T. S. Eliot.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.